Elasmogen, which is part of the Deepbridge Life Sciences EIS fund, recently secured £8 million in their latest funding round. This investment should enable the Aberdeen-based business to continue developing its pipeline of next-generation drugs through pre-clinical trials.
Elasmogen is a biopharmaceutical company located in the thriving biologics cluster in Aberdeen, Scotland. The Company is rapidly progressing a pipeline of next-generation soloMER™ products for the treatment solid-tumour cancers, systemic inflammatory diseases and inflammatory conditions of the gut. Discovering and developing soloMERs™ for the treatment of auto-immune mediated, inflammatory diseases. Utilising its unique soloMER™ platform, Elasmogen exploits the power of biologics as drugs but in small, simple, and stable formats that are amenable to site-specific delivery.
Dr Caroline Barelle, Chief Executive Officer at Elasmogen said:
“Securing this investment is truly transformational for Elasmogen and will enable us to progress our first soloMER drugs into the clinic as well as bolster and advance our exciting product pipeline. With the opening of the new BioHub here in Aberdeen later this year, an initiative led by Opportunity North East, combined with this investment and the quality of our new and existing investors, the company is well positioned to make a significant impact in the therapeutic biologics arena.”
Being led by industry professionals with broad experience that covers both big Pharma and early-stage biotech. The Elasmogen team has a demonstrated track-record of delivering biologic drugs to the clinic and of securing company exits via trade-sale and IPO.
Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).
Other News
